Reproducible demonstrations in mouse models of AD of beneficial effects of the CYP46A1 expression increase or CYP46A1 pharmacologic activation justified the safety and tolerability phase 1 study of EFV (Sustiva) in patients with mild cognitive impairment due to AD (NCT03706885 trial called EPAD). This evidence concerns the gene CYP46A1 and Alzheimer disease.